Spots Global Cancer Trial Database for gastroesophageal junction cancer
Every month we try and update this database with for gastroesophageal junction cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | NCT04882241 | Gastric Cancer Gastroesophagea... | Pembrolizumab Placebo Cisplatin Capecitabine 5-fluorouracil Docetaxel Oxaliplatin Leucovorin | 18 Years - | Merck Sharp & Dohme LLC | |
| Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ | NCT04061928 | PD-1 Chemoradiothera... Gastroesophagea... | PD-1 | 18 Years - 75 Years | Peking University | |
| PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer | NCT05033392 | Stomach Neoplas... | Toripalimab Inj... | 18 Years - 79 Years | Shenzhen People's Hospital | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer | NCT02501603 | Gastric Cancer Gastroesophagea... | afatinib paclitaxel | 19 Years - | Yonsei University | |
| A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer | NCT02178956 | Gastric Cancer Gastroesophagea... | BBI608 Paclitaxel Placebo | 18 Years - | Sumitomo Pharma America, Inc. | |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | NCT04082364 | Gastric Cancer Gastroesophagea... HER2-positive G... | margetuximab Retifanlimab Tebotelimab Trastuzumab Chemotherapy | 18 Years - | MacroGenics | |
| FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) | NCT02661971 | Stomach Cancer Gastroesophagea... | Docetaxel Oxaliplatin Calciumfolinat 5-Fluorouracil Ramucirumab | 18 Years - 70 Years | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT03653507 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab oxaliplatin capecitabine placebo | 18 Years - | Astellas Pharma Inc | |
| Spanish Registry of Esophagogastric Cancer | NCT04958720 | Esophageal Canc... Gastric Cancer | Surgery Chemotherapy, a... Radiotherapy | 18 Years - 100 Years | Fundación Sociedad Española de Oncologia Médica | |
| Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction | NCT06250894 | PD-1 Neoadjuvant Che... Gastroesophagea... | PD-1inhibitor | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | NCT03221426 | Gastric Cancer Gastroesophagea... | Pembrolizumab Placebo Cisplatin Capecitabine 5-fluorouracil Docetaxel Oxaliplatin Leucovorin | 18 Years - | Merck Sharp & Dohme LLC | |
| STRENGTH Expansion | NCT04520867 | Esophageal Canc... Gastroesophagea... | STRENGTH | 18 Years - | University of Colorado, Denver | |
| Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | NCT02494583 | Gastric Adenoca... | Pembrolizumab Cisplatin 5-FU Capecitabine Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | NCT06346392 | Gastric Cancer Gastroesophagea... | AZD0901 AZD0901 Ramucirumab+ pa... Paclitaxel Docetaxel Irinotecan TAS-102 Apatinib | 18 Years - 130 Years | AstraZeneca | |
| Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer | NCT00858338 | Gastric Cancer Stomach Cancer | Potentially cur... Floxuridine (IP... Adjuvant Chemor... | 18 Years - | NYU Langone Health | |
| A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer | NCT03271073 | Gastric Cancer | Apatinib | 18 Years - 75 Years | Beijing Friendship Hospital | |
| STRENGTH Expansion | NCT04520867 | Esophageal Canc... Gastroesophagea... | STRENGTH | 18 Years - | University of Colorado, Denver | |
| Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma. | NCT03529266 | Esophageal Canc... Gastroesophagea... Anastomotic Lea... | Porcine Fibrin ... Surgery | 18 Years - 80 Years | Sun Yat-sen University | |
| Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: | NCT06411171 | Gastroesophagea... | Pembrolizumab p... | 18 Years - 75 Years | Xijing Hospital of Digestive Diseases | |
| Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab | NCT04276493 | Breast Cancer Gastric Cancer Gastroesophagea... | ZW25 Docetaxel Tislelizumab Capecitabine Oxaliplatin | 18 Years - | BeiGene | |
| Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | NCT00183898 | Gastric Cancer Esophageal Canc... | oxaliplatin, ca... | 18 Years - | University of Southern California | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer | NCT01743365 | Gastric Cancer Gastroesophagea... | Cisplatin-5FU-A... | 18 Years - | Hellenic Cooperative Oncology Group | |
| Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | NCT01813253 | Gastric Cancer Gastroesophagea... | Irinotecan Nimotuzumab | 20 Years - | Kuhnil Pharmaceutical Co., Ltd. | |
| Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer | NCT02726399 | Gastric Cancer Gastroesophagea... | Ramucirumab Trastuzumab Capecitabine Cisplatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | NCT04510285 | Esophagogastric... Gastric Cancer Gastric Tumor Esophageal Canc... Esophageal Neop... Esophageal Tumo... GastroEsophagea... Gastroesophagea... Gastroesophagea... Gastroesophagea... | Trastuzumab Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | NCT02370498 | Gastric Adenoca... Gastroesophagea... | pembrolizumab paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer | NCT04999332 | Gastric Cancer Gastric Adenoca... Effects of Chem... Toxicity Due to... | leucovorin, oxa... | 20 Years - | National Cheng-Kung University Hospital | |
| Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer | NCT00858338 | Gastric Cancer Stomach Cancer | Potentially cur... Floxuridine (IP... Adjuvant Chemor... | 18 Years - | NYU Langone Health | |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | NCT06219941 | Gastric Cancer Gastroesophagea... Pancreatic Aden... | AZD0901 5-Fluorouracil Leucovorin l-leucovorin Irinotecan Nanoliposomal I... Gemcitabine | 18 Years - | AstraZeneca | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | NCT04510285 | Esophagogastric... Gastric Cancer Gastric Tumor Esophageal Canc... Esophageal Neop... Esophageal Tumo... GastroEsophagea... Gastroesophagea... Gastroesophagea... Gastroesophagea... | Trastuzumab Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients | NCT00526110 | Gastrointestina... | 5-Fluorouracil Docetaxel Oxaliplatin | 18 Years - | M.D. Anderson Cancer Center | |
| A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer | NCT02027948 | Localized Stage... Gastroesophagea... | nutritional and... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| Spanish Registry of Esophagogastric Cancer | NCT04958720 | Esophageal Canc... Gastric Cancer | Surgery Chemotherapy, a... Radiotherapy | 18 Years - 100 Years | Fundación Sociedad Española de Oncologia Médica | |
| PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer | NCT05033392 | Stomach Neoplas... | Toripalimab Inj... | 18 Years - 79 Years | Shenzhen People's Hospital | |
| Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer | NCT00858338 | Gastric Cancer Stomach Cancer | Potentially cur... Floxuridine (IP... Adjuvant Chemor... | 18 Years - | NYU Langone Health | |
| Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer | NCT01747707 | Gastric Cancer Gastroesophagea... | Docetaxel Cisplatin S-1 | 18 Years - 75 Years | ChineseAMS | |
| Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea | NCT02538562 | Gastric Cancer Gastroesophagea... | - | Hoffmann-La Roche | ||
| CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | NCT05187182 | Gastric Cancer Esophageal Canc... Stomach Cancer Esophagus Cance... Gastroesophagea... | CA-4948 Nivolumab Pembrolizumab Trastuzumab mFOLFOX7 | 18 Years - | Washington University School of Medicine | |
| A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. | NCT05322577 | Gastric Cancer Gastroesophagea... | Bemarituzumab CAPOX SOX Nivolumab | 18 Years - 100 Years | Amgen | |
| A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer | NCT01748773 | Gastric Cancer Gastroesophagea... | Oxaliplatin Radiation Capecitabine Trastuzumab | 18 Years - 75 Years | Hoffmann-La Roche | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | NCT04882241 | Gastric Cancer Gastroesophagea... | Pembrolizumab Placebo Cisplatin Capecitabine 5-fluorouracil Docetaxel Oxaliplatin Leucovorin | 18 Years - | Merck Sharp & Dohme LLC | |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | NCT05329766 | Gastrointestina... | Domvanalimab Quemliclustat Zimberelimab Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | NCT01774851 | HER-2 Gene Ampl... Esophagus Cance... Gastroesophagea... Stomach Cancer | MM-111 Paclitaxel Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer | NCT02726399 | Gastric Cancer Gastroesophagea... | Ramucirumab Trastuzumab Capecitabine Cisplatin | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | NCT06219941 | Gastric Cancer Gastroesophagea... Pancreatic Aden... | AZD0901 5-Fluorouracil Leucovorin l-leucovorin Irinotecan Nanoliposomal I... Gemcitabine | 18 Years - | AstraZeneca | |
| A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer | NCT02027948 | Localized Stage... Gastroesophagea... | nutritional and... | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer | NCT05395780 | Gastric Cancer Gastroesophagea... | MAX-40279 | 18 Years - 80 Years | Maxinovel Pty., Ltd. | |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | NCT03652077 | Cervical Cancer Gastric Cancer Stomach Cancer Gastroesophagea... Esophageal Canc... Hepatocellular ... Melanoma Uveal Melanoma Merkel Cell Car... Mesothelioma MSI Non-small Cell ... NSCLC Ovarian Cancer Squamous Cell C... Small Cell Lung... Renal Cell Carc... RCC Triple-negative... Urothelial Carc... Mismatch Repair... | INCAGN02390 | 18 Years - | Incyte Corporation | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) | NCT02661971 | Stomach Cancer Gastroesophagea... | Docetaxel Oxaliplatin Calciumfolinat 5-Fluorouracil Ramucirumab | 18 Years - 70 Years | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer | NCT05395780 | Gastric Cancer Gastroesophagea... | MAX-40279 | 18 Years - 80 Years | Maxinovel Pty., Ltd. | |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | NCT05233436 | Advanced Solid ... Gastric Cancer Gastroesophagea... Urothelial Canc... Non Small Cell ... Head and Neck S... | PF-07265028 Sasanlimab | 18 Years - 99 Years | Pfizer | |
| Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction | NCT06250894 | PD-1 Neoadjuvant Che... Gastroesophagea... | PD-1inhibitor | 18 Years - 70 Years | Wuhan Union Hospital, China | |
| A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | NCT02335411 | Gastric Adenoca... Gastroesophagea... | pembrolizumab cisplatin 5-FU capecitabine | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | NCT01774851 | HER-2 Gene Ampl... Esophagus Cance... Gastroesophagea... Stomach Cancer | MM-111 Paclitaxel Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | NCT06346392 | Gastric Cancer Gastroesophagea... | AZD0901 AZD0901 Ramucirumab+ pa... Paclitaxel Docetaxel Irinotecan TAS-102 Apatinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
